M.d. Anderson Cancer Center

This study tests whether a personalized cell therapy called liso-cel can stop large B-cell lymphoma from returning in patients who still have traces of cancer DNA after standard treatment. Ten adults who have completed first-line therapy but show minimal residual disease will rec…

This study tests a drug called imetelstat in 30 adults with certain blood cancers (MDS/MPN) that haven't responded to standard treatments. The goal is to see if the drug can help control the disease and to check for side effects. Participants must be 18 or older and meet specific…

This study tests whether combining dasatinib and ropeginterferon can better control chronic myeloid leukemia in its early phase. About 40 adults newly diagnosed with CML will receive the drug combo, and researchers will monitor side effects and how well the disease responds. The …

This early-phase study tests the safety of an engineered virus called M032, injected directly into the tumor, for children and adults with diffuse midline glioma (a type of brain cancer) who have already received standard radiation therapy. The study enrolls 20 participants aged …

This early-phase study tests whether adding the experimental drug SAR445877 to standard chemotherapy (FOLFOX6) and bevacizumab is safe for people with a specific type of advanced colorectal cancer called microsatellite stable (MSS). About 41 adults who have not had prior treatmen…

This early-phase trial tests whether adding a new drug (APG1252) to standard chemotherapy (AZA) can help control high-risk acute myeloid leukemia (AML). About 52 adults with relapsed, refractory, or certain newly diagnosed AML will take part. The main goal is to check safety and …

This early-phase trial tests a new drug called revumenib alongside standard chemotherapy for children and young adults (ages 6 months to 21 years) with acute leukemia. The study has two parts: first, finding the safest dose of revumenib, then checking if that dose helps control t…

This early-phase study tests a combination of three drugs (avutometinib, defactinib, and everolimus) in people with recurrent endometrial cancer that has a specific genetic change called a RAS mutation. The main goal is to find a safe dose and check for side effects. About 31 par…

This early-stage trial tests a new treatment for people with advanced pancreatic cancer that has spread or cannot be removed. It combines specially engineered immune cells (NK cells) with a daily pill called belzutifan. The goal is to see if the treatment is safe and to find the …

This early-phase study tests a new treatment called TRICK-NK, which uses specially engineered immune cells from a donor, combined with the drug T-Dxd, for people with advanced breast cancer that has stopped responding to standard therapies. The main goals are to find the safest d…

This early-phase study at M.D. Anderson tests whether drug combinations chosen based on each patient's tumor characteristics can help control metastatic colorectal cancer. About 100 adults with a specific type of colorectal cancer (non-MSI-H/pMMR) will receive personalized treatm…

This study tests a combination of three drugs (cemiplimab, fianlimab, and ipilimumab) given before surgery to people with stage III or IV melanoma that can be removed. The goal is to see if the treatment is safe and helps shrink the cancer. About 20 adults who have not had prior …

This early-phase trial tests a new treatment using specially engineered natural killer (NK) cells from donated cord blood. The cells are modified to better recognize and attack cancer cells, and to resist signals that would normally stop them. The study includes up to 60 adults w…

This early-phase study tests a new drug called PLM-102 in 12 adults with acute myeloid leukemia (AML) that has returned or not improved after standard therapy. The main goal is to find the highest safe dose and watch for side effects. This is a first step to see if the drug might…

This study compares two types of voice prostheses (the Provox ActiValve and standard ones) in 48 adults who have had their voice box removed due to cancer. The goal is to see if using the ActiValve routinely reduces how often the device needs to be replaced each year. Participant…

This study tests whether a new treatment combining specially designed immune cells (ONC-PluReceptor NK cells) with two antibody drugs (epcoritamab and tafasitamab) can control B-cell Non-Hodgkin lymphoma that has returned or not responded to prior therapies. About 30 adults aged …

This early-stage study tests an oral chemotherapy drug, cladribine, combined with two other drugs (low-dose cytarabine and venetoclax) for people with acute myeloid leukemia (AML). The first part finds the safest dose; the second part checks if that dose helps control the disease…

This early-phase trial tests a new approach for people with melanoma that has spread to the lining of the brain (leptomeningeal disease). Doctors will take a patient's own immune cells (CD8+ T cells), grow them in a lab, and inject them directly into the spinal fluid. The goal is…

This study tests whether a combination of three drugs (cladribine, ruxolitinib, and venetoclax) can control a rare and aggressive blood cancer called T-cell prolymphocytic leukemia (T-PLL) that has returned or not responded to prior therapy. About 36 adults will receive the drug …

This early-phase study tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) in 18 adolescents and young adults aged 12 to 30 whose T-cell acute lymphoblastic leukemia or lymphoma has returned or not responded to prior treatment. The main goal…

This study tests whether giving blinatumomab as a shot under the skin can control leftover leukemia cells (called measurable residual disease) in adults with B-cell acute lymphoblastic leukemia. About 40 participants will receive the drug to see if it is safe and helps prevent th…

This early-phase trial tests whether combining two drugs, blinatumomab and revumenib, is safe for adults with a rare and aggressive form of acute lymphoblastic leukemia (ALL) that has a KMT2A gene change. The study includes people whose cancer has returned or not responded to tre…

This study tests a drug called zanzalintinib in 16 people with a rare nasal cancer (olfactory neuroblastoma) that has come back or spread. The goal is to see if the drug can control the cancer and to check its safety. Participants must not have had similar drugs before and must b…

This pilot study tests whether infliximab can safely reverse insulin dependence in people who developed diabetes after checkpoint inhibitor cancer treatment. About 14 participants will receive the drug and be monitored for side effects and blood sugar control. The goal is to see …

This early-phase trial tests two drugs, olutasidenib and ziftomenib, in adults with a certain type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The study first finds a safe dose, then checks if the combination helps control the cancer. About 20…

This study tests whether a new contrast agent called gadopiclenol can help MRI scans find leptomeningeal disease (cancer spread to the brain and spinal cord lining) earlier. About 40 adults with solid tumors who have unclear MRI results will receive the contrast and be monitored …

This study tests if taking a blood sample directly from veins inside the brain is safe and can provide the same detailed information about high-grade glioma as a traditional surgical biopsy. About 20 adults with suspected or confirmed high-grade glioma will participate. The goal …

This study tests whether psilocybin, a compound found in certain mushrooms, can prevent or lessen nerve damage caused by chemotherapy in people with breast, colorectal, or head and neck cancer. About 83 participants will receive either psilocybin, a placebo, or standard supportiv…

This study tests a virtual group lifestyle program for women with stable HR+/HER2- metastatic breast cancer. The goal is to see how much support helps them stick with healthy habits like diet and exercise. About 100 women will join, and the program is done from home using a smart…

This study looks at what helps or hinders prostate cancer patients from completing genetic testing, which is recommended for many. Researchers will use this information to create and test a decision support tool that educates patients and helps them decide whether to get tested. …

This study looks at whether recording your cancer doctor visit helps you remember what was said and share it with family or caregivers who couldn't be there. About 200 adults with advanced cancer will be asked to record their appointment. A week later, they'll answer questions ab…

This study aims to understand how a man's migration history and social factors affect his quality of life after a prostate cancer diagnosis. Researchers will interview 40 Black immigrant men from Sub-Saharan Africa and the Caribbean who were diagnosed within the last 10 years. Th…

This study tests a program to help people with certain genetic mutations talk to their at-risk relatives about testing and treatment. About 2,100 participants will either get standard care or the program plus free genetic counseling. The goal is to see if the program improves fam…

This study talks to 120 adults with breast, colorectal, lung, or prostate cancer across Texas to learn what makes it easier or harder to get timely cancer treatment. Researchers will conduct interviews and focus groups, covering different insurance types. No new treatments or dru…